_version_ 1785113452919914496
author Cholley, Bernard
Bojan, Mirela
Guillon, Benoit
Besnier, Emmanuel
Mattei, Mathieu
Levy, Bruno
Ouattara, Alexandre
Tafer, Nadir
Delmas, Clément
Tonon, David
Rozec, Bertrand
Fellahi, Jean-Luc
Lim, Pascal
Labaste, François
Roubille, François
Caruba, Thibaut
Mauriat, Philippe
author_facet Cholley, Bernard
Bojan, Mirela
Guillon, Benoit
Besnier, Emmanuel
Mattei, Mathieu
Levy, Bruno
Ouattara, Alexandre
Tafer, Nadir
Delmas, Clément
Tonon, David
Rozec, Bertrand
Fellahi, Jean-Luc
Lim, Pascal
Labaste, François
Roubille, François
Caruba, Thibaut
Mauriat, Philippe
author_sort Cholley, Bernard
collection PubMed
description
format Online
Article
Text
id pubmed-10539228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105392282023-09-30 Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study Cholley, Bernard Bojan, Mirela Guillon, Benoit Besnier, Emmanuel Mattei, Mathieu Levy, Bruno Ouattara, Alexandre Tafer, Nadir Delmas, Clément Tonon, David Rozec, Bertrand Fellahi, Jean-Luc Lim, Pascal Labaste, François Roubille, François Caruba, Thibaut Mauriat, Philippe Ann Intensive Care Correction Springer International Publishing 2023-09-29 /pmc/articles/PMC10539228/ /pubmed/37770809 http://dx.doi.org/10.1186/s13613-023-01193-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Cholley, Bernard
Bojan, Mirela
Guillon, Benoit
Besnier, Emmanuel
Mattei, Mathieu
Levy, Bruno
Ouattara, Alexandre
Tafer, Nadir
Delmas, Clément
Tonon, David
Rozec, Bertrand
Fellahi, Jean-Luc
Lim, Pascal
Labaste, François
Roubille, François
Caruba, Thibaut
Mauriat, Philippe
Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title_full Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title_fullStr Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title_full_unstemmed Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title_short Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study
title_sort correction: overview of the current use of levosimendan in france: a prospective observational cohort study
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539228/
https://www.ncbi.nlm.nih.gov/pubmed/37770809
http://dx.doi.org/10.1186/s13613-023-01193-y
work_keys_str_mv AT cholleybernard correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT bojanmirela correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT guillonbenoit correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT besnieremmanuel correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT matteimathieu correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT levybruno correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT ouattaraalexandre correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT tafernadir correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT delmasclement correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT tonondavid correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT rozecbertrand correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT fellahijeanluc correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT limpascal correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT labastefrancois correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT roubillefrancois correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT carubathibaut correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT mauriatphilippe correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy
AT correctionoverviewofthecurrentuseoflevosimendaninfranceaprospectiveobservationalcohortstudy